Predictors of recurrence of atrial fibrillation within the first 3 months after ablation
Matthias Daniel Zink(Maastricht University), Ulrich Schotten(Maastricht University), Luigi Di Biase(Albert Einstein College of Medicine), Sakis Themistoclakis(Texas Cardiac Arrhythmia), Gerhard Hindricks(Humboldt-Universität zu Berlin), Jonathan P. Piccini(Clinical Research Institute), Stef Zeemering(Maastricht University), Paulus Kirchhof(Universität Hamburg), Tom De Potter(Onze Lieve Vrouwziekenhuis Hospital), Lluı́s Mont(Hospital Clínic de Barcelona), Hussein R. Al‐Khalidi(Clinical Research Institute), Derick Todd(University of Liverpool), Joseph de Bono(University Hospitals Birmingham NHS Foundation Trust), Bayes de Luna Antoni(Universitat Autònoma de Barcelona), Winnie Chua(University of Birmingham), Luis A. Escobar(Louisiana State University), David Callans(Hospital of the University of Pennsylvania), Jens Cosedis Nielsen(Aarhus University), Isabelle C Van Gelder(University of Groningen), Karl Georg Hæusler(Universitätsklinikum Würzburg)
Cited by 42
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
|EP Europace|2016|6.5k
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
|European Heart Journal|2016|6.4k
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k